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The aim of the study was to investigate ITGA2B and ITGB3 genetic polymorphisms and to evaluate the variability in the platelet
function in healthy Chinese subjects. The genetic sequence of the entire coding region of the ITGA2B and ITGB3 genes was
investigated. Adenosine diphosphate-induced platelet aggregation, glycoprotein IIb/IIIa content, bleeding time, and coagulation
indexes were detected. Thirteen variants in the ITGA2B locus and 29 variants in the ITGB3 locus were identified in the Chinese
population.The rs1009312 and rs2015049were associatedwith themean platelet volume.The rs70940817was significantly correlated
with the prothrombin time.The rs70940817 and rs112188890were related with the activated partial thromboplastin time, and ITGB3
rs4642 was correlated with the thrombin time and fibrinogen. The minor alleles of rs56197296 and rs5919 were associated with
decreased ADP-induced platelet aggregation, and rs55827077 was related with decreased GPIIb/IIIa per platelet. The rs1009312,
rs2015049, rs3760364, rs567581451, rs7208170, and rs117052258 were related with bleeding time. Further studies are needed to
explore the clinical importance of ITGA2B and ITGB3 SNPs in the platelet function.
1. Introduction
Platelet aggregation plays a central role in the pathogenesis
of acute thrombosis in coronary heart disease, stroke, and
peripheral arterial disease. The cellular events leading to
platelet aggregation aremediated by the binding of fibrinogen
to the glycoprotein (GP)IIb/IIIa receptor of platelets as a final
common pathway. GPIIb/IIIa is a platelet-specific, surface
membrane receptor and also called alpha IIb beta 3 (aIIb
𝛽3) in the integrin nomenclature and thus plays a primary
role in both platelet adhesion and thrombus formation at
the vascular injury site [1]. A large interindividual number
variability for GPIIb/IIIa receptors expressed on the platelet
surface is commonly observed [2, 3]. Moreover, a defect in
the GPIIb/IIIa complex or a qualitative abnormality of this
complex is seen inGlanzmann’s thrombasthenia patientswith
impaired platelet aggregation and increased bleeding [4].
The ITGA2B gene encodes the aIIb subunit (GPIIb),
whereas the ITGB3 gene encodes 𝛽3 (GPIIIa). The ITGA2B
spanning 17 kb has 30 exons, whereas the ITGB3 spanning
46 kb has 15 exons; they are closely located on chromosome
17q21.32 without evidence for coordinated expression [5].
A few studies have linked single-nucleotide polymorphisms
(SNPs) in ITGA2B and ITGB3 with increased or decreased
platelet responses to various agonists and the risk of acute
coronary syndrome and atherosclerosis [6–8].
A common polymorphism in the ITGB3, known as the
human platelet antigen 1 (HPA-1b, PlA2, or rs5918), arises
from a single-nucleotide change at position 1565 in Exon2 of
ITGB3, resulting in a leucine (PlA1) to proline (PlA2) substi-
tution at residue 33 [9].The SNP has been extensively studied
as an inherited risk factor for acute coronary syndrome
and for its effect on the platelet function [6–8]. The HPA-
3 (rs5910) polymorphism results from a thymine to guanine
base change that leads to the replacement of isoleucine (HPA-
3a) by serine (HPA-3b) at codon 843 of GPIIb (ITGA2B).This
polymorphism may potentially influence the activity of the
GPIIb/IIIa complex and associate with thrombosis [10].
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According to the aforementioned studies, GPIIb/IIIa was
believed to be a platelet-platelet contact receptor playing an
important role in platelet aggregation, and its SNPswere asso-
ciated with platelet hyperreactivity and have an effect on the
pharmacodynamics of antiplatelet drugs. However, limited
informationwas available on other genetic polymorphisms of
ITGA2B and ITGB3 in Asian populations or their association
with the platelet function [11, 12]. Moreover, the prevalence
of the PlA2 allele (rs5918) is dependent on ethnicity, with a
frequency of approximately 15/100 in Caucasian populations
[13] falling to less than 1/100 in Oriental populations [12, 14].
In this study, regions of the exons of ITGA2B and ITGB3
genes were sequenced in 86 unrelated healthy Chinese. In
addition, the association between genetic variants of ITGA2B
and ITGB3 exons and the adenosine diphosphate- (ADP-)
induced platelet aggregation, GPIIb/IIIa content, bleeding
time, and coagulation indexes was investigated in 55 of the
86 subjects.
2. Materials and Methods
2.1. Study Design. The research was conducted in compliance
with the Declaration of Helsinki. The study protocol was
approved by the Ethical Review Board of the Peking Univer-
sity First Hospital. All subjects gave their written informed
consent prior to participation in the study. Healthy native
Chinese subjects (𝑛 = 86) between 18 and 45 years of age with
a bodymass index (BMI) of 19–24 kg/m2 were included in the
study, and their genotypes were unknown.
All the subjects were considered healthy on the basis of
theirmedical history, physical examination, vital signs (blood
pressure, pulse rate, and temperature), safety laboratory tests
(blood chemistry, hematological tests, and urinalysis), and 12-
lead electrocardiography.
TheADP-induced platelet aggregation (transmission,𝑇%
max), GPIIb/IIIa content (GPIIb/IIIa per platelet), bleeding
time, and coagulation indexes, including the mean platelet
volume (MPV), platelet count (PLT), prothrombin time (PT),
activated partial thromboplastin time (aPTT), fibrinogen
(FIB), and thrombin time (TT) were detected in 55 of the 86
subjects. None of the donors had taken any medication for 2
weeks before blood collection.
2.2. ADP-Induced Platelet Aggregation. Blood was collected
in 3.8% sodium citrate tubes, and platelet-rich plasma (PRP)
was obtained by centrifuging blood at 1000 revolutions per
minute (rpm) for 10 minutes at room temperature. The PRP
was collected in a fresh tube and platelet was counted by
Platelet Counter PL100 (Sysmex, Kobe, Japan). Platelet-poor
plasma (PPP) was obtained by centrifuging the remaining
blood at 3000 rpm for 10 minutes at room temperature, and
platelet numbering PRP was adjusted to 250 × 109/L by PPP.
Detection was completed within 1 hour after sampling.
Platelet aggregation was determined by the turbidimetric
method using 20 umol/L ADP as the agonist. After zero
setting with the PPP, assays were performed in platelet-rich
plasma in a Chrono-Log aggregometer. Platelet aggregation
was quantified as the maximum change in light transmission
occurring within 5 minutes of addition of agonist.
2.3. GPIIb/IIIa Content. GPIIb/IIIa on the platelet surface
was evaluated in the PRP as the maximal binding of a 125I-
labeled GPIIb/IIIa integrin antiplatelet antibody F(ab)
2
[15].
The PRP was fixed with equal volume of anticoagulant-
fixative solution (10mmol/L EDTA-Na
2
, 0.2% glutaralde-
hyde, and 0.02% sodium azide dissolved in PBS, pH 7.4).
After stored at 4∘C, overnight, platelet was washed by
Tyrode’s solution twice and resuspended in Tyrode solu-
tion, containing 0.35% bovine serum albumin (concentration
adjusted to 1 × 1011 platelets/L), and sodium azide was
added at final concentration of 0.02% (V/V) to preserve the
platelet at 4∘C for a week-long before assay. For detection,
the platelet suspension (100 𝜇L) was added to a 0.5mL
Eppendorf tube and then incubated with 100 𝜇L of antibody
(containing 20,000 cpm of labeled monoclonal antibody
(McAb) and 0.8 𝜇g of unlabeled McAb) at 37∘C for 1 hour,
after washed with 0.35% bovine serum albumin/Tyrode’s
solution for three times. The radioactivity count of the
precipitate in the tube was measured. Assuming that one
monoclonal antibody would only bind one GP molecule
on the platelet membrane, the number of GP molecules
on the platelet membrane was calculated as number of GP
molecules/platelet = (binding rate× amount of antibody (g)×
Avogadro’s number)/(molecular weight of antibody× platelet
count).
2.4. Bleeding Time. The skin bleeding time was carried out
using the Simplate-II device (General Diagnostics, NJ, USA).
A sphygmomanometer cuff was inflated on the patient’s arm
to 40mmHg. The arm was supported at the level of the
heart, and a muscular area on the volar aspect distal to the
antecubital area was identified and swabbed with alcohol.
The Simplate-II device was used to perform the incision
perpendicular to the antecubital fossa. Bloodwas blottedwith
sterile filter paper every 30 seconds until blood no longer
stained the paper. The time from incision to stopping of
bleeding was recorded.
2.5. Genetic Analysis. Genomic DNA was extracted from
peripheral whole blood samples of each subject using a DNA
Purification Kit (Wizard; Promega, WI, USA). After the
polymerase chain reaction (PCR) products were obtained, all
samples were directly sequenced to determine the SNPs in
ITGA2B and ITGB3 (Life Technologies Biotechnology Co.,
Ltd., China).
Primers required for PCR amplification and sequencing
were designed according to the wild-type ITGA2B and
ITGB3 sequences reported in theGenBank (NG 008331.1 and
NG 008332.1, resp.). Tables 1 and 2 describe the primer pairs
used to amplify the promoters, the 5󸀠- and 3󸀠-untranslated
regions (UTRs), the entire coding regions and the intron-
exon junctions of the ITGA2B and ITGB3 genes.
2.6. Data Analysis. TheVariant Reporter v1.1 (Life Technolo-
gies Biotechnology Co., Ltd.) software suite was used for
the initial analysis of the sequence, including base calling,
fragment assembly, SNP, and sequence insertions/deletions
detection. Polymorphisms of ITGA2B and ITGB3 genes
were named according to the genomic reference sequences
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Forward primer (5󸀠 to 3󸀠) Reverse primer (5󸀠 to 3󸀠) Amplified regionNC 000017.11
Length
(bp)
ITGA2B-1 TCCTCCTCTTCCGCTTACCG TACTACCACCGTGCTAGTCC 44389728–44390630 848
ITGA2B-2 Exon1 CCAATATGGCTGGTTGAG AACTTCCCTTACGGCTCA 44389267–44390059 792
ITGA2B-3 Exon1 CCAGTGCAGCTCACCTTCTA GATGAGGGAAATGGAACAGA 44388253–44389368 1115
ITGA2B-4 Intron1 TATGAACCACTCCACCCT TTGGCACTCTTGATTCTG 44388169–44389006 837
ITGA2B-5 Exon2, Exon3 ACCGCTGGTTCTTGTTGC CCTACGGGCGTCTTCTCA 44385649-44386479 830
ITGA2B-6 Exon4–Exon6 TACAGGGCACAGGGAACAATC AGAGGCTCTGGGAGGACACG 44384990–44385810 820
ITGA2B-7 Exon7, Exon8 TCCTGGCGGCTATTATTTCT GCACCGACGACATATTCTGG 44384339–44385186 847
ITGA2B-8 Exon9–Exon11 ATTTGCGCCCTTGTCCTC AGCCGAATCGCCCATAGA 44383538–44384605 1067
ITGA2B-9 Exon12 CCCTCTGTCTCCCTTTCC CATCCAGTCTCCCACCAA 44383189–44383838 649
ITGA2B-10 Exon13, Exon14 CCTAGTCTCCTGGGATGTTC TCACGGGTGTCTTGGTCT 44380390–44381163 773
ITGA2B-11 Exon14–Exon17 TAATCGCCAATTCTGACCC CACATCCCACCTTCTCCTG 44379854–44380682 828
ITGA2B-12 Exon18 ACCCACTGGACTTGTTCATC TGTGACTTGGCACTAACCC 44379610–44379957 347
ITGA2B-13 Exon19, Exon20 TGGACGACAGAGCGAGAC GGCCATACCTCGACATTG 44378354–44378989 635
ITGA2B-14 Exon21 CATGTGACAGTCCCTTGA AAAGTCACTCACCCAAGGA 44377551–44377933 382
ITGA2B-15 Exon22 CTTGGAGGGTGAAGACTGG CAACTCCTGACCTCCAGTGA 44376833–44377179 346
ITGA2B-16 Exon23–Exon25 CCAGGTCTAACTTCAGTGTG GCTCTGGCAGGAAGATCTGT 44375629–44376523 894
ITGA2B-17 Exon26 TCCGACCTGCTCTACATCC CGGGCTTGCTCACATAGTC 44375277–44375913 636
ITGA2B-18 Exon27, Exon28 ATGACCCTCCCTGCATCTC CACCTTGACACCTGCCTTT 44374500–44375317 817
ITGA2B-19 Exon29 GCACGCATGGTTCAACGT CCTCCCGAGTAGCTGAGATT 44374025–44374731 706
ITGA2B-20 Exon30 AAAGGCATCCATTTGTGA TGTTGGTAAGGCTGGTCTC 44371896–44372566 670
ITGB3-1 CAGGAGGTGGAGGATTGT GCTGGATTCTTGGGACAC 47252637–47253474 837
ITGB3-2 Exon1 CGGTTCAGAGAAGGCATTCAG GCTCCAAGTCCGCAACTTGA 47253373–47254015 642
ITGB3-3 Intron1 TTGGCGTAGGAGGTGAGTGA CCGCAGGAAGCCAAGTTGAA 47253929–47254518 589
ITGB3-4 Intron1 TTGGCGTAGGAGGTGAGTGAG GAAGTTGCAGTGAGCCGAGAA 47253929–47255063 1134
ITGB3-5 Exon2 ATTGGGAAAGTTGGGAAGG GAAAGGGCAGCAGTGGTT 47274335–47274773 438
ITGB3-6 Exon3 AGGCTGGTCTTGAACTCTTG CTCCACCTTGTGCTCTAT 47283116–47283612 496
ITGB3-7 Exon4 GGGCTTTCTGGTTTGCTT CATTTCCCTCCCATTCTC 47284329–47284978 649
ITGB3-8 Exon5 TGTCTGGGTAACTGTGGT CATCTGCCTACTTTGCTG 47286124–47286725 601
ITGB3-9 Exon6 TCCAAGGACTGGGACTGA ATGATGCTGCTGCTATGC 47286919–47287483 564
ITGB3-10 Exon7, Exon8 AGCCCAAGCAAGATAAGT GGAGAAGGCAGTAAGACC 47289597–47290393 796
ITGB3-11 Exon9 AAACTGGGCTCCAATAAC TGAGGGACTGAAGGTAAAG 47290561–47291406 845
ITGB3-12 Exon10 CAGGGCAGGGAACAACTT GGATTGGTCCTTATACTCAAAA 47292050–47292720 670
ITGB3-13 Exon11 GAGCAAGTCCTGCCATAC TCACAGAGTGTCCTCCATAA 47299101–47299890 789
ITGB3-14 Exon12 CAGAAATGGCATAGGGTT TCTTGCTGAGTCTGTGGG 47300168–47300824 656
ITGB3-15 Exon13 CTTGAATCTAGGCATCGT GTATTGAACTCCTGACCC 47302581–47303050 469
ITGB3-16 Exon14 CCTCAAGTAGGTCCCAGTG AACATGACCACCCAAAGC 47307158–47307721 563
ITGB3-17 Exon15 CTCATCTCCTCCTGTTATTT TGACATTCTCCCAACCTAC 47309941–47310337 396
NG 008331.1 andNG 008332.1, respectively. Novel SNPswere
named as ITGA2B-number or ITGB3-number in the present
study.
2.7. Statistical Analysis. The association between two param-
eters was assessed by Pearson’s two-tailed test. Statistical
analyses were performed using the Statistical Package for
Social Sciences software program forWindows (SPSS version
16.0). A 𝑃 value of 0.05 was considered significant.
3. Results
3.1. ITGA2B and ITGB3Variations. Within the Chinese sam-
ple, 13 and 29 variants in ITGA2B and ITGB3were identified,
respectively. Two novel ITGB3 SNPs with MA(F) > 0.02
were found, which were not reported in the National Cen-
ter for Biotechnology Information (NCBI) dbSNP database
(https://www.ncbi.nlm.nih.gov/snp/). The allele frequencies
andHardy–Weinberg equilibrium test results of the identified
polymorphic sites are shown in Tables 3 and 4.
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Table 4: Association between individual ITGA2B and ITGB3 SNPs and the ADP induced platelets aggregation, GPIIb/IIIa content, bleeding
time, PLT, and MPV (mean ± SD).
dbSNP Genotypes 𝑁 Aggregation max
𝑇%
GPIIb-IIIa per
platelet Bleeding time (s) PLT (10
9/L) MPV (fL)
rs3760364 AA 48 36.6 ± 15.3 45937.1 ± 15214.0 281.3 ± 97.4 277.0 ± 70.87 9.48 ± 0.84
AT 7 27.4 ± 16.1 41060.9 ± 15560.7 364.3 ± 87.3 257.7 ± 83.7 9.51 ± 0.66
𝑃 0.148 0.433 0.038 0.512 0.911
rs7208170
GG 18 38.5 ± 16.2 48835.0 ± 13746.0 326.7 ± 100.8 255.1 ± 62.1 9.14 ± 0.74
GA 24 35.1 ± 14.3 45714.9 ± 15783.1 288.8 ± 86.6 290.6 ± 82.8 9.63 ± 0.80
AA 13 31.7 ± 17.1 39709.0 ± 15545.1 249.2 ± 109.1 272.1 ± 60.4 9.68 ± 0.84
𝑃 0.229 0.105 0.030 0.428 0.051
rs55827077
GG 18 39.9 ± 16.2 49297.7 ± 14047.7 315.0 ± 86.2 253.2 ± 62.6 9.24 ± 0.65
GC 22 35.1 ± 13.0 47150.7 ± 13706.9 279.5 ± 102.4 291.9 ± 85.5 9.55 ± 0.85
CC 14 30.6 ± 18.1 36518.1 ± 16661.9 287.1 ± 113.3 280.1 ± 55.2 9.66 ± 0.93
𝑃 0.091 0.021 0.401 0.251 0.141
rs567581451 -/- 49 35.0 ± 14.4 45317.6 ± 14892.6 282.2 ± 99.1 277.3 ± 73.7 9.56 ± 0.80
-/insTCCCC 6 38.5 ± 24.4 45306.8 ± 19136.0 370.0 ± 64.8 252.3 ± 56.8 8.88 ± 0.62
𝑃 0.609 0.999 0.040 0.428 0.054
rs117052258
GG 29 36.7 ± 16.3 44811.1 ± 14492.1 319.7 ± 93.6 277.1 ± 79.2 9.37 ± 0.82
GC 21 37.3 ± 13.3 48026.0 ± 15188.4 268.6 ± 105.4 267.9 ± 59.9 9.58 ± 0.80
CC 4 18.3 ± 14.8 31964.5 ± 18104.4 232.5 ± 61.8 309.7 ± 84.4 9.70 ± 1.01
𝑃 0.165 0.539 0.028 0.764 0.288
rs1009312a
GG 19 39.3 ± 15.9 46470.7 ± 13798.6 326.8 ± 84.2 276.4 ± 95.0 9.13 ± 0.61
GA 22 34.0 ± 14.6 48883.3 ± 14927.5 287.7 ± 101.3 272.7 ± 58.6 9.64 ± 0.88
AA 14 32.3 ± 16.6 38145.0 ± 16040.8 250.7 ± 105.0 275.0 ± 59.1 9.71 ± 0.82
𝑃 0.189 0.160 0.027 0.944 0.029
rs56197296
TTTGT/TTTGT 42 37.7 ± 15.9 45398.1 ± 14564.7 285.0 ± 94.7 280.5 ± 76.3 9.41 ± 0.81
TTTGT/del 11 30.9 ± 10.2 45262.9 ± 18722.4 330.0 ± 116.2 249.6 ± 57.1 9.78 ± 0.79
del/del 2 11.5 ± 7.8 43895.5 ± 16431.0 225.0 ± 63.6 288.0 ± 21.2 9.30 ± 1.13
𝑃 0.014 0.916 0.695 0.433 0.416
rs5919
TT 31 38.8 ± 16.1 45342.5 ± 14029.1 299.0 ± 96.6 283.7 ± 78.8 9.34 ± 0.84
TC 16 34.9 ± 12.5 47696.5 ± 17544.9 315.0 ± 105.6 247.7 ± 58.6 9.64 ± 0.73
CC 8 23.3 ± 13.8 40455.6 ± 15470.6 217.5 ± 67.6 292.9 ± 60.5 9.73 ± 0.85
𝑃 0.015 0.634 0.130 0.728 0.148
Note: Pearson’s two-tailed test was used to analyze correlation between genotype and parameter. ars1009312 was completely linked with rs2015049.
3.2. Linkage Disequilibrium Analysis. Using the detected
polymorphisms greater than 0.01 in frequency [MA(F) >
0.02], linkage disequilibrium (LD) was analyzed for |𝐷󸀠|
and 𝑟2 values (Figure 1). For ITGA2B, rs5911 was completely
linked with rs850730 (𝑟2 = 1.00), and rs5910 was strongly
linked with rs850730 and rs5911 (𝑟2 = 0.95). For ITGB3, com-
plete LD was observed between rs4642 and rs4634 (𝑟2 =
1.00). Other LD results are shown in Figure 1. A new SNP
ITGB3-09 was found for which MA(F) in this study was
0.402.
The Hardy–Weinberg equilibrium 𝑃 values of rs1009312
and rs2015049 were <0.001. The possible reason is that the
sample in this study may have a Chinese population of other
ethnic groups besides the Han population. Those two SNPs
were not included in the LD analysis.
3.3. Correlation of ADP-Induced Platelet Aggregation, GPIIb/
IIIa Content, Bleeding Time, and Coagulation Indexes. The
GPIIb/IIIa contents, present as average numbers of GPIIb/
IIIa receptor in each platelet, were associated with ADP-
induced platelet aggregation (𝑟 = 0.280, 𝑃 = 0.038), PLT
(𝑟 = −0.522, 𝑃 < 0.001), PT (𝑟 = 0.453, 𝑃 = 0.001), and
TT (𝑟 = 0.545, 𝑃 < 0.001) (Figures 1 and 2). The relationship
between GPIIb/IIIa content and APTT was not significant
(𝑟 = 0.242, 𝑃 = 0.075), while the association between ADP-
induced platelet aggregation and APTT was moderately
significant (𝑟 = 0.267, 𝑃 = 0.049) (Figure S1). The bleeding
time had no association with other parameters. It had a
negative association trend with MPV but was not significant
(𝑟 = −0.244, 𝑃 = 0.073). The PLT was associated with PT
(𝑟 = −0.415, 𝑃 = 0.002) and TT (𝑟 = −0.363, 𝑃 = 0.007).
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Figure 1: Linkage disequilibrium (LD)map of ITGB2A and ITGB3 SNPs along with their locations in the ITGB2A and ITGB3 genes. Variants
present at >1% frequency were included in the LD analysis using the statistics |𝐷󸀠| and 𝑟2. Red depicts a significant linkage between an SNP
pair. Numbers inside the square indicate 𝑟2 × 100. (a) ITGB2A. (b) ITGB3.
The FIB was negatively correlated with TT (𝑟 = −0.409,
𝑃 = 0.002).
3.4. Impact of ITGA2B and ITGB3 SNPs on ADP-Induced
Platelet Aggregation, GPIIb/IIIa Content, Bleeding Time, and
Coagulation Indexes. For ITGA2B, only one SNP rs3760364
was related with the bleeding time (𝑃 = 0.038) (Table 4).
No significant correlation or trend was observed between
ITGA2B SNPs and other parameters.
For ITGB3, the mean values of ADP-induced platelet
aggregation of homozygous mutant genotypes in rs56197296
and rs5919 were lower than those of heterozygous mutations
and wild type. Moreover, the GPIIb/IIIa per platelet was
associated with rs55827077. A trend of GPIIb/IIIa per platelet
was observed among rs70940817 GG (45), GA (9), andAA (1)
carriers (43807.7 ± 14157.5, 51086.8 ± 19368.0, 61277, resp.,
𝑃 = 0.093), although it did not reach a significant level.
The bleeding time was significantly related with rs3760364,
rs7208170, rs567581451, and rs117052258 (Table 4).
In the present study, SNPs related with PLT were not
found. ITGB3 rs1009312, which is completely linked with
rs2015049, was significantly associated with the MPV
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Figure 2: Correlations of the maximal level of ADP-induced
platelet aggregation and GPIIb/IIIa content in healthy volunteers.
𝑟, coefficient of correlation; 𝑃, significance of correlation (Pearson’s
test here and elsewhere).
(Table 4). ITGB3 rs70940817 was correlated with the PT and
APTT (𝑃 = 0.002 and 𝑃 = 0.003, resp.). The coagulation
indexes and their 𝑃 values are summarized in Table 5.
4. Discussion
In this study, 13 variants in the ITGA2B locus and 29 variants
in the ITGB3 locus in the Chinese population were observed.
Two of the 29 variants located in ITGB3 were novel SNPs
with MA(F) > 0.02. Variants in ITGA2B and ITGB3 genes
displayed significant interethnic differences in the global
populations (Table 6). The C allele frequency of SNP rs5918
(T/C), located in the ITGB3 gene, was only inhomogeneously
distributed at 0.7% in the Chinese population, while it is
common in whites and Africans (allele frequency 13.7%
versus 12.8%). The following alleles of SNPs, rs7208170A,
rs55827077C, rs11871251A, rs1009312G, and rs2015049G, were
found to be more common in the Han Chinese and Africans
(37%∼50%) than in the European ancestry (10%∼20%). In
the ITGA2B gene, the rs5911 was completely linked with
rs850730 and strongly linked with rs5910 in the Chinese
population in this study, and all the three SNPswere common
in whites and Asians. However, the rs5911 was not found in
Africans. According to the ethnicity difference described in
the preceding text, resequencing of the ITGA2B and ITGB3
genes in the Chinese population was believed to be very
important to reveal the function of SNPs.
Variation in theMPV or PLT can have a profound impact
on differences in the platelet function between individuals
[16, 17], and these traits have a strong genetic component [18–
21]. However, limited information is available for Asians. In
the present study, the A alleles of rs1009312 and rs2015049,
located in ITGB3, were positively associated with the MPV
(𝑃 = 0.029). The MPV had a trend in rs7208170 alleles but
did not reach a significant level (𝑃 = 0.051). The differ-
ence between PLT and SNPs in ITGA2B or ITGB3 was not
significant.
The APTT and PT are clinical tests commonly used to
indicate coagulation factor deficiencies [22, 23], activated
coagulation, and risk of venous thromboembolism [24, 25].
To date, two genome-wide association studies (GWAS) of
APTT and PT conducted in the European ancestry have been
reported. One study identified genome-wide significant asso-
ciations of APTT and variants at F12 (MIM 610619), KNG1
(MIM 612358), and HRG (MIM 142640) [26]. In the other
research, the GWAS for APTT and PT was conducted and
replicated genome-wide significant associations at KNG1,
HRG, F11, F12, and ABO for APTT and identified significant
associations at the F7 and PROCR/EDEM2 regions for PT.
Eight genetic loci accounted for ∼29% of the variance in
APTT, and two loci accounted for ∼14% of the variance in PT
[27]. In this study, the association of APTT, PT, FIB, and TT
with ITGA2B and ITGB3SNPs was investigated. The A allele
of ITGB3 rs70940817 was found to significantly correlate with
the elevated APTT and PT (𝑃 = 0.003 and 𝑃 = 0.002, resp.).
The T allele of ITGB3 rs112188890 was related with APTT
(𝑃 = 0.029), and the G allele of ITGB3 rs4642 was associated
with TT and FIB (𝑃 = 0.015 and 𝑃 = 0.029, resp.).
TheADP-induced platelet aggregation test was often used
to identify the platelet function and the efficacy of antiplatelet
drugs. Jones et al. detected 1327 SNPs and investigated their
correlation with ADP or collagen-related peptide-induced
platelet aggregation in 500 healthy northern European sub-
jects. This identified 17 novel associations with the platelet
function (𝑃 < 0.005) accounting for approximately 46% of
the variation in response [28]. In this study, the minor allele
of rs56197296 and rs5919 was found to be associated with the
decreased ADP-induced platelet aggregation (𝑃 = 0.014 and
𝑃 = 0.015, resp.).
GPIIb/IIIa is the central receptor of platelet aggrega-
tion. The variations of GPIIb/IIIa amount expressed on a
platelet surface might affect the platelet-aggregating activity.
Many studies reported that the rs5918 correlated with the
GPIIb/IIIa receptor expression [29]; however, many conflict
studies have also been published [3, 30]. O’Halloran et al.
investigated whether three polymorphisms of the GPIIIa
promoter (−468G/A, −425A/C, and −400C/A) influenced
the RNA expression and receptor density in the platelets
of patients with cardiovascular disease [3]. They found a
threefold variation between the subjects in the number of
GPIIb/IIIa receptors expressed per platelet, although no
association between the receptor density and the PlA2 or
the three promoter polymorphisms was demonstrated. In the
present study, rs55827077, which was located at the promoter
region of the GPIIIs gene at position −145, was related with
GPIIb/IIIa per platelet.
The bleeding time is a test that evaluates the platelet
function in vivo. A prolonged bleeding time can result from
platelet abnormality, Von Willebrand factor deficiency, or
vascular disorders such as Ehlers–Danlos syndrome. A dis-
ruption of platelet aggregation results in a prolongation of the
bleeding time [31]. In this study, the bleeding time was related
with rs3760364 of ITGA2B and rs7208170, rs567581451, and
rs117052258 of ITGB3 (𝑃 < 0.05). No previous study report-
ing on the effect of SNPs on the bleeding time was found.The
mechanism of the relationship needs to be further examined.
However, a negative trend between the bleeding time and
MPV (𝑟 = −0.244, 𝑃 = 0.073) was observed. Moreover,
rs1009312 and rs2015049 were found to significantly associate
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Table 5: Association between individual ITGA2B and ITGB3 SNPs and the coagulation indexes (mean ± SD).
Genotypes 𝑁 PT (s) APTT (s) TT (s) FIB (g/L)
rs112188890a
CC 42 10.9 ± 1.08 31.2 ± 2.13 15.7 ± 2.22 2.52 ± 0.45
CT 12 11.2 ± 1.35 32.2 ± 2.73 14.7 ± 1.59 2.72 ± 0.44
TT 1 12.5 36.7 16.5 2.72
𝑃 0.126 0.029 0.299 0.173
rs4642b
AA 27 10.9 ± 1.20 30.9 ± 2.25 16.1 ± 2.36 2.43 ± 0.42
AG 21 11.3 ± 1.08 32.0 ± 2.34 15.2 ± 1.71 2.68 ± 0.44
GG 7 10.4 ± 1.01 32.3 ± 2.79 14.2 ± 1.39 2.76 ± 0.45
𝑃 0.770 0.088 0.015 0.029
rs70940817
GG 45 10.7 ± 1.08 31.1 ± 2.19 15.2 ± 2.01 2.52 ± 0.42
GA 9 11.8 ± 1.02 32.8 ± 2.26 16.8 ± 2.34 2.75 ± 0.54
AA 1 12.7 37.2 15.75 3.10
𝑃 0.002 0.003 0.078 0.069
MPV, mean platelet volume; PLT, platelet count; PT, prothrombin time; APTT, activated partial thromboplastin time; FIB, fibrinogen; TT, thrombin time.
Note: Pearson’s two-tailed test was used to analyze correlation between genotype and parameter.
aStrong LD was observed between rs112188890 and rs117414137 (𝑟2 = 0.99); bcompletely LD was observed between rs4642 and rs4634.
Table 6: Comparison of ITGA2B and ITGB3 allele frequencies in different ethnic groups.
dbSNP MA(F)a
Number This study Chinese Asianb European-ancestryc Africand
ITGA2B-01 rs3760364 T(0.052) T(0.012) T(0) T(0)
ITGA2B-08 rs850730 G(0.477) G(0.467) G(0.297) G(0.437)
ITGA2B-11 rs5911 G(0.477) G(0.467) G(0.305) G(0)
ITGA2B-12 rs5910 T(0.465) T(0.442) T(0.376) T(0.432)
ITGB3-03 rs7208170 A(0.419) A(0.496) A(0.194) A(0.431)
ITGB3-05 rs7208055 A(0.221) A(0.225) A(0.117) A(0.356)
ITGB3-06 rs55827077 C(0.448) C(0.417) C(0.158) C(0.39)
ITGB3-08 rs117052258 C(0.227) C(0.208) NA NA
ITGB3-10 rs11871251 A(0.453) A(0.482) A(0.199) A(0.373)
ITGB3-12 rs12188890 T(0.116) T(0) T(0.023) T(0)
ITGB3-16 rs1009312 G(0.417) A(0.434) A(0.125) A(0.432)
ITGB3-17 rs2015049 G(0.471) A(0.478) A(0.138) A(0.413)
NF. rs5918 C(0) C(0.007) C(0.137) C(0.128)
ITGB3-18 rs56197296 delTTTGT(0.169) NA NA NA
ITGB3-19 rs5919 C(0.262) C(0.232) C(0.049) C(0.187)
ITGB3-23 rs4642 G(0.331) G(0.31) G(0.283) G(0.306)
ITGB3-25 rs4634 A(0.331) A(0.350) A(0.283) A(0.331)
ITGB3-29 rs70940817 A(0.076) NA NA NA
dbSNP, single nucleotide polymorphism database; MA(F), minor allele (frequency); SNP, single nucleotide polymorphisms; NF, not found; NA, not available.
aResource of MP(F)s was from GenBank and HapMap, https://www.ncbi.nlm.nih.gov/snp/; bHan Chinese in Beijing, China (CHB), or CHB + Japanese in
Tokyo, Japan (JPT), if there is no CHB data in the SNP; cUtah residents with Northern and Western European ancestry from the CEPH collection (CEU);
dYoruba in Ibadan, Nigeria (YRI).
with both bleeding time and MPV. Further, the minor alleles
of rs7208170 and rs567581451, whichwere significantly related
with the bleeding time, had a trend with the MPV among
genotypes, although they did not reach a significant level (𝑃 =
0.051 and 𝑃 = 0.054, resp.). However, no relationship was
observed among SNPs, bleeding time, andMPV in rs3760364
and rs117052258.
In this study, a positive correlation of the level of ADP-
induced aggregation and GPIIb/IIIa content was detected
in healthy volunteers. This correlation is consistent with a
previous report. Yakushkin et al. investigated the relationship
between the number of GPIIb/IIIa and the level of ADP-
induced aggregation in a group of 35 healthy volunteers and
found positive and significant correlations between the level
of platelet aggregation induced by different ADP doses (from
1.25 to 20mmol/L) and the number of GPIIb/IIIa [32].
A strong positive correlation was observed between
GPIIb/IIIa per platelet and PLT, PT, and TT (𝑃 < 0.01).
Although the TT was strongly correlated with GPIIb/IIIa per
platelet (𝑟 = 0.545, 𝑃 < 0.001), the relationship of SNPs/TT
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and SNPs/GP (IIb/IIIa) content is not linked. For example,
ITGB3 rs4642 was significantly related with the TT (𝑃 =
0.015), while the value of GPIIb/IIIa per platelet had no trend
among rs4642 genotypes (𝑃 = 0.789). The other coagulation
indexes were the same. Therefore, the relationship between
SNPs and GPIIb/IIIa content cannot be deduced from the
correlation of coagulation indexes and SNPs.
Some of the significant correlations between SNPs and
platelet function parameters in the present study were not
reported previously, which may be due to the reason that
SNPs with low MA(F) in the European ancestry were not
selected as candidate SNPs in previous studies. For example,
the GWAS-genotyping platforms lack the coverage of low
frequency/rare variants [33]. Moreover, LDmight be another
reason, if different genetic patterns (haplotypes) are present
in different populations [3].
A possible limitation of the current study is the limited
number of subjects. After stratification, the number of sub-
jects in each genotypic group was small, thereby limiting
further haplotype association analysis and accession of small
effects of an SNP with a small minor allele frequency.
5. Conclusion
In summary, as ethnicity difference might limit the interpre-
tation of the function of SNPs, resequencing the ITGA2B and
ITGB3 genes and investigating their functions in the Chinese
population are very important. In the present study, nine
SNPs were found to associate with indexes of platelet and
coagulation haemostasis. Newer studies are needed, particu-
larly, to further assess the clinical importance of the above-
discussed SNPs in disease susceptibility and antiplatelet
drugs pharmacodynamics. Further studies should pay more
attention to the roles of ITGA2B and ITGB3 SNPs in ethnic
variations.
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